2025年中国创新药的BD(业务拓展)出海引爆全球医药行业,2026年这一趋势有望持续。 根据国家药监局此前公布的数据,2025年,中国创新药对外授权交易总金额超过1300亿美元,授权交易数量超过150笔,创历史新高。BD热潮在2026年仍在持续,2026年前两个月已经有多笔BD官宣。 2月11日,“港股小核酸药物第一股”瑞博生物(6938.HK)宣布,与Madrigal 达成全球独家许可协议...
Source Link2025年中国创新药的BD(业务拓展)出海引爆全球医药行业,2026年这一趋势有望持续。 根据国家药监局此前公布的数据,2025年,中国创新药对外授权交易总金额超过1300亿美元,授权交易数量超过150笔,创历史新高。BD热潮在2026年仍在持续,2026年前两个月已经有多笔BD官宣。 2月11日,“港股小核酸药物第一股”瑞博生物(6938.HK)宣布,与Madrigal 达成全球独家许可协议...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.